Metastatic renal cell carcinoma presenting as a paranasal sinus mass: the importance of differential diagnosis by RALLI, MASSIMO et al.
Case Report
Metastatic Renal Cell Carcinoma Presenting as a Paranasal
Sinus Mass: The Importance of Differential Diagnosis
Massimo Ralli,1 Giancarlo Altissimi,2 Rosaria Turchetta,2 andMario Rigante3
1Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Rome, Italy
2Department of Sense Organs, Audiology Section, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
3Department of Otorhinolaryngology, Catholic University of Sacred Heart, Rome, Italy
Correspondence should be addressed to Massimo Ralli; massimo.ralli@uniroma1.it
Received 25 July 2016; Revised 15 November 2016; Accepted 14 December 2016; Published 11 January 2017
Academic Editor: Marco Berlucchi
Copyright © 2017 Massimo Ralli et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metastases in the paranasal sinuses are rare; renal cell carcinoma is the most common cancer that metastasizes to this region. We
present the case of a patient with a 4-month history of a rapidly growing mass of the nasal pyramid following a nasal trauma,
associated with spontaneous epistaxis and multiple episodes of hematuria. Cranial CT scan and MRI showed an ethmoid mass
extending to the choanal region, the right orbit, and the right frontal sinus with an initial intracranial extension. Patient underwent
surgery with a trans-sinusal frontal approach using a bicoronal incision combinedwith an anteriormidfacial degloving; histological
exam was compatible with a metastasis of clear cell renal cell carcinoma. Following histological findings, a total body CT scan
showed a solitary 6 cmmass in the upper posterior pole of the left kidney identified as the primary tumor. Although rare, metastatic
renal cell carcinoma should always be suspected in patients with nasal or paranasal masses, especially if associated with symptoms
suggestive of a systemic involvement such as hematuria. A correct early-stage diagnosis ofmetastatic RCC can considerably improve
survival rate in these patients; preoperative differential diagnosis with contrast-enhanced imaging is fundamental for the correct
treatment and follow-up strategy.
1. Introduction
Renal cell carcinoma (RCC) is the most common kidney
cancer, with approximately 35,000 new cases in the US
each year [1]; RCC mainly affects male patients between
40 and 60 years old [2]. Common presentation symptoms
include hematuria (40%), flank pain (40%), and a palpable
abdominal mass (25%) [3]. Approximately 30% of patients
with renal cell carcinoma present with metastatic disease
[4]; target organs are lung (75%), soft tissues (36%), bone
(20%), liver (18%), cutaneous sites (8%), and central nervous
system (8%) [5, 6]. Metastases in the paranasal sinuses are
rare [7]; however, RCC is the most common cancer that
metastasizes to this region. Prognosis of metastatic RCC is
poor [8]; the survival rate ranges between 15 and 30% at
5 years [9] in case of a single metastasis and between 0
and 7% in patients with multiple metastases [10]. Metastatic
RCC is often resistant to chemotherapy and radiotherapy [11];
numerous agents targeting VEGF and non-VEGFR pathways
have been proposed during the last decade for the treatment
of advanced RCC [12–18].
We present the case of a patient with a single, rapidly
growing mass in the upper portion of the nasal pyramid,
with late, postnasal surgery histological diagnosis of renal cell
carcinoma that allowed primary tumor identification.
2. Case Presentation
A 72-year-old man was referred to our institution with a 4-
month history of a voluminous mass in the upper portion
of the nasal pyramid following a nasal trauma. He had been
treated a few weeks earlier at a different ENT service for
a massive spontaneous epistaxis. The patient also reported
a long history of hematuria, previously attributed to renal
tuberculosis occurring over 40 years before. At admission,
a cranial CT scan showed a large soft tissue ethmoid mass
extending to the right and left choanal region, the right orbit,
the right frontal sinus, and an initial intracranial extension
Hindawi Publishing Corporation
Case Reports in Otolaryngology
Volume 2017, Article ID 9242374, 5 pages
https://doi.org/10.1155/2017/9242374
2 Case Reports in Otolaryngology
(a) (b)
Figure 1: MRI in the axial (a) and sagittal (b) planes showing a soft tissue ethmoid mass extending to the right and left choanal region, the
right orbit, the right frontal sinus, and an initial intracranial extension with partial erosion of the crista galli.
Figure 2:The excised mass; histological exam was consistent with a
clear cell renal cell carcinoma.
with partial erosion of the crista galli. MRI confirmed the
evidence found at computed tomography (Figure 1). Fine
needle aspiration showed typical epithelial tissue and clear-
cytoplasm cells interpreted as pericytes. Preoperative local
biopsy was not performed due to the history of severe
epistaxis and the high risk of massive bleeding during the
procedure.
The patient underwent surgery with a trans-sinusal
frontal approach using a bicoronal incision combinedwith an
anterior midfacial degloving to excise the mass; however, the
right orbital and especially the initial intracranial extension
did not allow a complete removal of the neoplasm. Consider-
able bleeding occurred during surgery.The histological exam
revealed a clear cell renal cell carcinoma (Figure 2). Based on
these findings, the patient underwent a total body CT scan
that showed a solitary 6 cm mass in the upper posterior pole
of the left kidney. Bone scintigraphy also revealed increased
uptake in the ethmoid and orbital region. Due to the poor
general conditions, no surgery was performed to remove the
primary tumor; the patient died 4 months later.
3. Discussion
Nasal cavity and paranasal sinus cancers are usually primary
tumors. Metastases to the paranasal sinuses are rarely found;
among them, renal cell carcinoma is the most common can-
cer to metastasize to this region (49%) followed, respectively,
by bronchus, urogenital ridge, breast, and gastrointestinal
tract [19, 20]. RCC can metastasize to any region of the body,
with a prevalence for lungs (75% of cases), regional lymph
nodes (65%), bone (40%), and liver (40%) [21]. Metastasis
to the head and neck regions account for about 15% of the
cases, targeting in order of frequency the paranasal sinuses,
the larynx, jaws, temporal bones, thyroid, and parotid glands
[22].
RCC tumor cells can reach the sinonasal region via two
routes: the first includes inferior vena cava, lungs, heart, and
the maxillary artery; the second involves the communication
of the avalvular vertebral venous plexus and the intracranial
venous plexus [23].Maxillary sinuses are themost commonly
involved sinuses by metastatic tumors (36%), followed by the
ethmoid (25%), frontal and sphenoid sinuses (17%), and nasal
cavity (11%) [24, 25].One of the first reports available in recent
literature to describe a renal clear cell carcinomametastatic to
the paranasal sinuses has been published by Matsumoto and
Yanagihara in 1982 [26]; afterwards several authors described
case reports of RCC presenting as metastatic diseases in the
paranasal sinuses. Available literature describes presentation
of RCC metastasis as a solitary periorbital [27] and orbital
mass [28], as a frontal sinus mass [29], as an ethmoid sinus
mass [30, 31], in the nasal cavity [32, 33], in the maxillary [34,
35], and sphenoid sinus [36–38]. In some cases, the extension
of the metastasis to the skull base has been described
[39].
Metastatic RCC to the sinonasal district has been
reported as the presenting sign of this disease in a few cases
[29, 34], while in others it followed or occurred simultane-
ously to primary cancer diagnosis. Presentation symptoms
are often limited to recurrent epistaxis [40–43] and the
presence of a primary renal cell carcinoma is recognized only
after surgical removal of the metastatic tumor via histologic
examination supported by immunohistochemical staining of
the specimen [5]. Rarely, metastasis in the sinonasal cavities
followed RCC diagnosis and treatment [44–46]; cases of
postsurgery metastasis in the head and neck district have
been described up to 12 years after surgery [47].
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The key point in RCC presenting with a sinonasal
metastasis is differential diagnosis with primary tumors
such as adenocarcinomas, angiofibromas, hemangiopericy-
tomas, melanomas, hemangiomas, metastatic tumors from
the breast and lungs, and, more rarely, systemic diseases
such as Wegener’s and midline granulomas [48]. In fact, in
such cases diagnostic delays, misdiagnosis, undertreatment,
and mismanagement could occur due to (1) the attribution
of the mass to a primary sinonasal cancer given the rare
nature of sinonasal metastasis or (2) to the overlook of
presenting symptoms such as recurrent epistaxis, swelling,
pain, and nasal obstruction. Hematuria can be considered
as an indicator of RCC; it has been reported that about 10%
of patients with RCC with distant metastasis exhibit massive
hematuria. However, intermittent hematuria may be present
in 90% of cases [3]. For this reason, patients presenting with
nasosinusal tumors also reporting hematuria should always
undergo systemic evaluation. Radiological examination with
CT scan and, secondly, MRI and angiography are necessary
in assessing the extent of the metastatic lesion. However,
it should be considered that RCC metastases have similar
radiological appearances to primary malignant lesions of
sinonasal cavities; some indicators of renal origin at CT
scan are enhancement, destruction, and lack of tumoral
calcification [6].
In this case, CT scan allowed the identification of a
neoformed paranasal sinus mass; however, only histological
exam identified the mass as a metastasis of RCC and led
to the execution of total body CT scan to identify primary
tumor. Although difficult, differential preoperative diagnosis
is fundamental for the correct treatment and follow-up
strategy; contrast-enhanced imaging plays a central role since
a preoperative biopsy of the nasal mass may be difficult
in these patients due to massive recurring bleeding and, in
some cases, may result in only necrotic tissue inconclusive
on histopathology [42].The ENT specialist, therefore, should
always suspect metastatic disease from primary sites external
to the head and neck region in patients with hypervascular
mass in the nasal cavity or paranasal sinuses and a history
of massive nasal bleeding and should complete preoperative
workupwith total bodyCT scan. Furthermore, it is important
to remark that metastatic tumors originating from primary
kidney masses are highly vascularized and surgeons should
expect significant haemorrhage during surgical removal. One
of the main advantages of a preoperative diagnosis of RCC
when approaching a patient with sinonasal mass is the prepa-
ration for management of severe perioperative bleeding, thus
implementing strategies to optimise the patient’s tolerance to
bleeding and to reduce the amount of bleedingmorbidity and
mortality.
Prognosis of metastatic RCC is poor; however, a correct
early-stage diagnosis of metastatic disease can considerably
improve survival rate: literature reports that excision of
solitary metastatic lesion of renal cell carcinoma following
nephrectomy results in a 41% survival at 2 years and 13%
survival at 5 years [48]. The sole excision of the metastatic
lesion, instead, significantly lowers survival rate [49]; patients
with multiple metastases have a 5-year survival rate between
0 and 7% [10].
Althoughmetastatic RCC is often resistant to chemother-
apy and radiotherapy, numerous agents targeting VEGF and
non-VEGFR pathways should be taken into account for the
treatment of advanced RCC. Multitargeted VEGF tyrosine
kinase inhibitors (TKIs) include sorafenib [12], sunitinib [13],
pazopanib [14], axitinib [15], and bevacizumab [16]; mTOR
inhibitors include temsirolimus [17] and everolimus [18].
Unfortunately, especially in cases of advanced neoplasms,
benefits are still time-limited and treatment decisions should
be based not only on guidelines but also on clinical con-
siderations, such as patient comorbidities, treatment toxicity,
prognostic factors, and molecular aspects of disease. In this
case, the poor general conditions of the patient prevented
additional treatment except for palliative pain management.
In conclusion, metastatic renal cell carcinoma should
always be suspected in patients with nasal or paranasal
masses, especially if associated with symptoms suggestive of a
systemic involvement such as hematuria; early-stage diagno-
sis of metastatic disease can considerably limit perioperative
complications and improve survival rate.
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